Stem-Cell Therapy Trials Miss Mark but Keep Hope Alive – Medscape
Medscape |
Stem–Cell Therapy Trials Miss Mark but Keep Hope Alive
Medscape A phase 2a trial found that IV administration of allogeneic ischemia-tolerant mesenchymal stem cells (itMSC) derived from a single healthy donor did not effect left ventricular (LV) function in 22 patients with nonischemic HF and an ejection fraction … Another Meeting, Another Mesenchymal Stem Cell Study (or Two), With Mixed Results |
